China Preventive Inhaler Market Size, Share, Trends & Forecast 2019-2025

Posted by Avinash on February 19th, 2020

China preventive inhaler market is anticipated to grow at a substantial CAGR of around 3.5% during the forecast period. High level of air pollution and the significant number of smokers in China is boosting the demand for preventive inhalers in the country. Additionally, the rising geriatric population susceptible to asthma and COPD within the country is also driving the demand for preventive inhalers. From June 2012 to May 2015, a survey was conducted by the Ministry of Health and Ministry of Science and Technology of China. About 51,000 citizens participated in the survey with 21,500 men and 29,500 women, according to which, it was estimated that about 100 million adults in 2015 had the problem of COPD in the country. The prevalence is higher in men as compared to women. As per the estimation, there were 68.4 million men and 31.5 million women affected by COPD. 

Request a Free Sample of our Report on China Preventive Inhaler Market:

The China preventive inhaler market is segmented on the basis of device type, application, and end-user. On the basis of the device, the market is sub-segmented into the metered dosed inhaler and dry powdered inhaler. The dry powder preventive inhaler is estimated to have the largest market share in the China preventive inhaler market due to providing an easy inhalation solution. Whereas, the market for metered dose preventive inhaler is estimated to be the fastest-growing at a CAGR during the forecast period owing to innovations and collaborations by the companies for the development of metered dosed inhaler. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed. 

A full Report of China Preventive Inhaler Market Available at:

Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing preventive inhalers to cater to a wide range of customers within the region and across the globe. The major players of the China preventive inhaler market include Cipla Ltd., Gerresheimer AG, 3M Co., AstraZeneca PLC, Aradigm Corp., Adherium Ltd., GlaxoSmithKline PLC, Novartis AG, ResMed Corp., Teva Pharmaceuticals Industries Ltd., and others. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players. For instance, in July 2019, Cipla Ltd. announced joint-venture (JV) with China-based Jiangsu Acebright Pharma to make respiratory drugs in China. This JV will allow Cipla to expand its footprints in the country and further strengthen its revenue stream. 

Market Segmentation

China Preventive Inhaler Market by Device Type

  • Metered Dose Inhaler
  • Dry Powder Inhaler

China Preventive Inhaler Market by Application

  • Asthma 
  • Chronic Obstructive Pulmonary Disease (COPD)

China Preventive Inhaler Market by End-User

  • Homecare
  • Hospitals and Clinics

Company Profiles

  • 3M Co.
  • Adherium Ltd.
  • Aradigm Corp.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • Gerresheimer AG
  • GlaxoSmithKline PLC
  • Koninklijke Philips N.V.
  • Novartis AG
  • ResMed Corp.
  • Sunovion Pharmaceuticals
  • Teva Pharmaceuticals Industries Ltd.

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Contact no: +1 646-755-7667, +91 780-304-0404

Like it? Share it!


About the Author

Joined: January 27th, 2020
Articles Posted: 123

More by this author